United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $548.95, for a total transaction of $5,215,025.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $178,102,984.85. This represents a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $532.78 on Friday. The stock has a market capitalization of $22.85 billion, a P/E ratio of 19.06, a price-to-earnings-growth ratio of 2.73 and a beta of 0.49. The company has a 50 day moving average price of $511.37 and a 200 day moving average price of $539.93. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the business earned $6.41 EPS. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of a number of recent research reports. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a research note on Thursday, October 1st. Morgan Stanley boosted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Finally, The Goldman Sachs Group began coverage on shares of United Therapeutics in a research note on Thursday, September 24th. They set a “sell” rating and a $321.00 target price for the company. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $627.31.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in UTHR. Callan Family Office LLC acquired a new stake in shares of United Therapeutics during the second quarter worth about $1,217,000. Nicholas Investment Partners LP boosted its position in shares of United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after purchasing an additional 3,766 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $3,359,000. Andra AP fonden grew its stake in United Therapeutics by 33.5% during the 2nd quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after buying an additional 8,760 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in United Therapeutics during the 4th quarter worth approximately $633,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.